| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.36.12.2709 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC245533 |
| https://europepmc.org/articles/PMC245533?pdf=render | ||
| P932 | PMC publication ID | 245533 |
| P698 | PubMed publication ID | 1336344 |
| P2093 | author name string | E. M. Bailey | |
| K. C. Lamp | |||
| M. J. Rybak | |||
| G. W. Kaatz | |||
| P2860 | cites work | Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin | Q40284247 |
| Suboptimal effect of daptomycin in the treatment of bacteremias | Q41217967 | ||
| Serum Dilution Test for Bactericidal Activity. II. Standardization and Correlation with Antimicrobial Assays and Susceptibility Tests | Q41296484 | ||
| MLTIDOSE: a multiple-dose simulation program for linear systems characterized by exponential functions | Q44638091 | ||
| Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies. | Q54325332 | ||
| LY146032: activity and resistance development in vitro. | Q54400060 | ||
| Comparison of in vitro activity of daptomycin, vancomycin and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics | Q69354779 | ||
| Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model | Q35276965 | ||
| Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis | Q35280233 | ||
| Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination | Q35285000 | ||
| Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations | Q35329160 | ||
| In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria | Q35345381 | ||
| Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations | Q35539120 | ||
| Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies | Q35540772 | ||
| Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies | Q35541070 | ||
| Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model | Q36754206 | ||
| Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria | Q36754855 | ||
| Daptomycin disrupts membrane potential in growing Staphylococcus aureus | Q36756893 | ||
| Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus | Q39817922 | ||
| Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032 | Q39828406 | ||
| In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic | Q39834787 | ||
| Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs | Q40087244 | ||
| Inhibition of membrane potential-dependent amino acid transport by daptomycin | Q40088405 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vancomycin | Q424027 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 2709-2714 | |
| P577 | publication date | 1992-12-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin | |
| P478 | volume | 36 |
| Q41646436 | A closer look at vancomycin, teicoplanin, and antimicrobial resistance |
| Q89551956 | Antibiotic Delivery Strategies to Treat Skin Infections When Innate Antimicrobial Defense Fails |
| Q35758983 | Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus |
| Q36642946 | Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin. |
| Q24682375 | Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells |
| Q34230034 | Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations |
| Q33981366 | Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi |
| Q42231593 | Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci |
| Q38990504 | Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain |
| Q40719299 | Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State. |
| Q33981048 | Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens |
| Q64095731 | Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions |
| Q35166213 | Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus |
| Q35368590 | Current perspectives on glycopeptide resistance. |
| Q44768109 | Daptomycin |
| Q35925535 | Daptomycin - a novel antibiotic against Gram-positive pathogens |
| Q34936759 | Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms |
| Q44641537 | Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations |
| Q44279637 | Daptomycin in complicated skin and soft tissue infections |
| Q40166184 | Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis |
| Q34882125 | Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects |
| Q34301398 | Daptomycin therapy for osteomyelitis: a retrospective study |
| Q53852746 | Daptomycin: a novel agent for Gram-positive infections. |
| Q36972980 | Daptomycin: a review 4 years after first approval |
| Q36864626 | Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia |
| Q36403749 | Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections |
| Q33920377 | Development of daptomycin for gram-positive infections |
| Q52595189 | Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model. |
| Q35121985 | Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration. |
| Q42873593 | Diminished in vitro antibacterial activity of oxacillin against clinical isolates of borderline oxacillin-resistant Staphylococcus aureus |
| Q39746366 | Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus |
| Q42131112 | Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model |
| Q46823300 | Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function |
| Q50991026 | Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. |
| Q41789314 | Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin |
| Q40602795 | Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model |
| Q41570351 | Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocar |
| Q53686599 | Failure of daptomycin to kill Staphylococcus aureus: impact of bacterial membrane fatty acid composition. |
| Q35752864 | Glycopeptide antibiotics: from conventional molecules to new derivatives |
| Q42727129 | Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model |
| Q37625071 | Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model |
| Q42110143 | In Vivo Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against Cefazolin |
| Q33980074 | In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model |
| Q28488311 | In vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pH |
| Q36492244 | In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants |
| Q39792691 | In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis |
| Q41825567 | In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure |
| Q40083539 | Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment |
| Q38646905 | Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review |
| Q36081079 | Mechanisms of action of newer antibiotics for Gram-positive pathogens |
| Q39513743 | Membrane-directed high bactericidal activity of (gold nanoparticle)-polythiophene composite for niche applications against pathogenic bacteria |
| Q42972012 | Methicillin-Resistant Staphylococcus aureus Prostatic Abscess in a Liver Transplant Recipient |
| Q34470713 | Natural products to drugs: daptomycin and related lipopeptide antibiotics |
| Q33245712 | New strategies for antibacterial drug design: targeting non-multiplying latent bacteria |
| Q35753477 | New therapies for pneumococcal meningitis |
| Q42363645 | Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations |
| Q28069334 | Optimizing the Clinical Use of Vancomycin |
| Q35136634 | Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium |
| Q90701768 | Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens |
| Q35102754 | Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages |
| Q33883648 | Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations |
| Q38194624 | The effects of pH on wound healing, biofilms, and antimicrobial efficacy. |
| Q44970812 | The efficacy of silver dressings and antibiotics on MRSA and MSSA isolated from burn patients |
| Q36328971 | The pharmacokinetic and pharmacodynamic properties of vancomycin |
| Q34330270 | The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections |
| Q34910366 | Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists |
| Q90021121 | Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials |
| Q33975592 | Vancomycin-resistant enterococci |
| Q84028196 | [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria] |
Search more.